Canakinumab shot for lower-risk MDS and related blood disorders
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests canakinumab, a medication that blocks inflammation, given as a skin (subcutaneous) injection. It is for adults with lower-risk myelodysplastic syndromes (MDS) or a related condition (chronic myelomonocytic leukemia or CCUS) to see if it can improve blood counts and reduce problems like anemia or transfusion needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older, and have MDS or chronic myelomonocytic leukemia, or CCUS as defined by the study
- For MDS groups: your disease must be “low” or “intermediate-1” risk based on study scoring (IPSS or IPSS-R)
- Have blood count problems (for at least 30 days), such as low hemoglobin or low platelets, per the study’s cutoffs
- If you are in the treatment-history group: your prior ESA or “hypomethylating” treatment must not have worked (or you must have relapsed after it) and you must have had enough treatment cycles; if you have del(5q), you must also have had lenalidomide
- You must be healthy enough for treatment: no serious uncontrolled infection, low enough liver and kidney lab levels, and you can do daily activities at a limited level (ECOG under 2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This trial tests three different treatments for people with a type of bone marrow disorder called low-risk myelodysplastic syndrome (MDS) that causes low red blood cells (anemia). The goal is to see which treatment works best and to find out more about the disease.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests a new combination of two drugs (axatilimab and ruxolitinib) for people with myelofibrosis or a related blood cancer called CMML. The goal is to see if the combination works better than standard treatments for these diseases.
This trial tests a new combination of drugs (nadunolimab plus azacitidine, sometimes with venetoclax) for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has not been treated much or has come back. The goal is to see if this combination can control the disease better.
Hear when a new Chronic Myelomonocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.